Evidence map›Paper›PMID 42693602›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Interleukin-1α Mediates Pancreatic Fibroblast Activation, Regulates Immune Cell Recruitment and Fibrosis in Acute and Chronic Pancreatitis.

Hala Mazloum, Shenja Buchholz, Hanna Schifter, Sabine Ameling, Leif Steil, Ben Lewin Becker, Elke Hammer, Georg Homuth, Uwe Völker, Barbara M Bröker and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hala MazloumDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Shenja BuchholzDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Hanna SchifterDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0009-0000-3992-7194
Sabine AmelingInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0002-3095-8362
Leif SteilInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0002-0733-8421
Ben Lewin BeckerDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0009-0009-7448-3432
Elke HammerInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0002-1507-0402
Georg HomuthInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0001-6839-0605
Uwe VölkerInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0002-5689-3448
Barbara M BrökerInstitute of Immunology, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0002-5020-8542
Lukas ZierkeDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Frank Ulrich WeissDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0003-3369-6369
Juliane Glaubitz *Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Matthias Sendler *Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.ORCID https://orcid.org/0000-0003-3554-9426

Funding

Deutsche Forschungsgemeinschaft DFG SE 2702/2-3Deutsche Forschungsgemeinschaft DFG SE 2702/4-1Deutsche Forschungsgemeinschaft GL 1096/1-1Deutsche Forschungsgemeinschaft GRK 2719 A1 C1Deutsche Forschungsgemeinschaft RTG 2901 SYLOBIODeutsche Forschungsgemeinschaft ZI 2071/2-1
6 · The paper itself

Abstract

Pancreatitis is a life-threatening inflammatory disease of the pancreas. The cytokine interleukin-1α has been demonstrated to act as an alarmin released by necrotic cells. In the present study, we investigated the influence of IL-1α on the immune response during acute and chronic pancreatitis. Following tissue injury, pancreatic acinar cells released IL-1α, which activates tissue-resident fibroblasts to differentiate toward a pro-inflammatory phenotype. By secreting chemokines and cytokines such as CXCL5, CCL2, and IL-6, these fibroblasts recruit immune cells to the pancreas. The absence of IL-1α reduces disease severity in acute pancreatitis and chemokine release. Furthermore, IL-1α primes fibroblasts to enhance the production of extracellular matrix-components by the up-regulation of pro-fibrotic receptors such as Il4ra, Il13ra1, and Tgfbr3. Therefore, the deletion of IL-1α significantly reduced the development of tissue fibrosis. A therapeutic blockade of the IL1R1-signaling by i.p. administration of the IL-1-receptor antagonist Anakinra showed the same effect; the severity of acute pancreatitis and fibrogenesis during chronic pancreatitis were reduced. In conclusion, the crosstalk between necrotic acinar cells and fibroblasts mediated by IL-1α plays a crucial role in acute inflammation of the pancreas and fibrogenic signaling. Blockade of IL1R1-signaling by Anakinra is therefore a promising therapeutic intervention for both acute and chronic pancreatitis.

Indexed as

acute pancreatitisAnakinrachronic pancreatitisfibroblastsfibrosisInterleukin 1 alpha

Identifiers

PMID42693602
PMCPMC13542390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.